Harvest Fund Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.93M | Sell |
7,900
-17
| -0.2% | -$11.6K | 0.16% | 91 |
|
|
2026
Q1 | $6.11M | Sell |
7,917
-37
| -0.5% | -$28.3K | 0.26% | 74 |
|
|
2025
Q4 | $6.14M | Buy |
7,954
+1,561
| +24% | +$1.06M | 0.23% | 82 |
|
|
2025
Q3 | $3.6M | Buy |
6,393
+366
| +6% | +$207K | 0.15% | 103 |
|
|
2025
Q2 | $3.16M | Sell |
6,027
-773
| -11% | -$431K | 0.15% | 108 |
|
|
2025
Q1 | $4.31M | Buy |
6,800
+440
| +7% | +$303K | 0.21% | 84 |
|
|
2024
Q4 | $4.39M | Buy |
6,360
+1,366
| +27% | +$1.15M | 0.2% | 85 |
|
|
2024
Q3 | $5.25M | Buy |
4,994
+1,523
| +44% | +$1.69M | 0.31% | 59 |
|
|
2024
Q2 | $3.65M | Sell |
3,471
-170
| -5% | -$165K | 0.26% | 62 |
|
|
2024
Q1 | $3.5M | Buy |
3,641
+2,449
| +205% | +$2.33M | 0.31% | 61 |
|
|
2023
Q4 | $1.03M | Buy |
1,192
+101
| +9% | +$83.2K | 0.16% | 77 |
|
|
2023
Q3 | $898K | Buy |
1,091
+479
| +78% | +$376K | 0.16% | 78 |
|
|
2023
Q2 | $440K | Sell |
612
-26
| -4% | -$20K | 0.09% | 119 |
|
|
2023
Q1 | $524K | Buy |
638
+53
| +9% | +$40K | 0.12% | 95 |
|
|
2022
Q4 | $420K | Buy |
585
+145
| +33% | +$107K | 0.11% | 118 |
|
|
2022
Q3 | $303K | Sell |
440
-81
| -16% | -$51K | 0.09% | 128 |
|
|
2022
Q2 | $308K | Hold |
521
| – | – | 0.09% | 114 |
|
|
2022
Q1 | $363K | Sell |
521
-39
| -7% | -$24.7K | 0.08% | 123 |
|
|
2021
Q4 | $360K | Buy |
560
+153
| +38% | +$94.1K | 0.06% | 146 |
|
|
2021
Q3 | $246K | Buy |
407
+306
| +303% | +$190K | 0.06% | 120 |
|
|
2021
Q2 | $58K | Sell |
101
-35
| -26% | -$17.7K | 0.01% | 387 |
|
|
2021
Q1 | $64K | Sell |
136
-178
| -57% | -$86.7K | 0.01% | 348 |
|
|
2020
Q4 | $151K | Sell |
314
-736
| -70% | -$397K | 0.01% | 187 |
|
|
2020
Q3 | $635K | Buy |
1,050
+528
| +101% | +$320K | 0.05% | 69 |
|
|
2020
Q2 | $317K | Buy |
522
+72
| +16% | +$40.9K | 0.03% | 98 |
|
|
2020
Q1 | $219K | Buy |
+450
| New | +$186K | 0.03% | 115 |
|
|
2019
Q2 | – | Sell |
-425
| Closed | -$175K | – | 418 |
|
|
2019
Q1 | $175K | Buy |
425
+191
| +82% | +$78.7K | 0.03% | 127 |
|
|
2018
Q4 | $87K | Buy |
+234
| New | +$85.6K | 0.02% | 194 |
|
|
2017
Q4 | – | Sell |
-58
| Closed | -$26K | – | 245 |
|
|
2017
Q3 | $26K | Hold |
58
| – | – | ﹤0.01% | 185 |
|
|
2017
Q2 | $28K | Buy |
+58
| New | +$25.4K | ﹤0.01% | 193 |
|
Other funds holding REGN
Harvest Fund Management's REGN Position: Q2 2026 in Review
Harvest Fund Management reduced its Regeneron Pharmaceuticals (REGN) stake by 0.21% in Q2 2026, selling an estimated $11.6K and leaving 7,900 shares worth $4.93M. The position accounts for 0.16% of the portfolio, ranked #91.
Harvest Fund Management first reported a position in REGN in Q2 2017 and has held it in 30 quarters since. The position peaked at $6.14M in Q4 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Harvest Fund Management held 7,900 shares of Regeneron Pharmaceuticals worth $4.93M as of Q2 2026.
- Harvest Fund Management sold 17 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $11.6K.
- Regeneron Pharmaceuticals made up 0.16% of Harvest Fund Management's portfolio in Q2 2026, its #91 holding.
- Harvest Fund Management first reported a position in Regeneron Pharmaceuticals in Q2 2017 and has held it in 30 quarters since.
- Harvest Fund Management's Regeneron Pharmaceuticals position peaked at $6.14M in Q4 2025.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Harvest Fund Management's 13F filing for Q2 2026, filed 20 Aug 2026.